Onkológia 1/2018

Decision making about the treatment of older patients with acute myeloblastic leukemia – case reports

Purpose: To describe the process of decision making about treatment of older patients with acute myeloblastic leukemia (AML) according to clinical condition and comorbidities. Case: We are presenting three cases of AML patients with initially more than 30% blasts in the bone marrow and in the peripheral blood. Conclusion: Azacitidin (AZA) was an optimal treatment option for three patients, older than 60 years, who achieved an overal survival similar to the results reported in the literature for the older patients with AML with initially more than 30% blasts in the bone marrow and in the peripheral blood.

Keywords: AML, older, azacitidin, survival, treatment